JP2013505289A - 腸管感染症の治療法 - Google Patents
腸管感染症の治療法 Download PDFInfo
- Publication number
- JP2013505289A JP2013505289A JP2012530351A JP2012530351A JP2013505289A JP 2013505289 A JP2013505289 A JP 2013505289A JP 2012530351 A JP2012530351 A JP 2012530351A JP 2012530351 A JP2012530351 A JP 2012530351A JP 2013505289 A JP2013505289 A JP 2013505289A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- pathogen
- antibodies
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
(実施例1)
抗生物質で治療を受けた、長期再発性の尿感染症を有する48歳の女性が、慢性の下痢を発症した。検便を数回実施した後、便中に毒素産生性のクロストリジウム・ディフィシレが検出された。これは、非伝染性株であったが、それにもかかわらず慢性の下痢を引き起こし、その下痢は1日当たり10〜15回生じ、時に失禁の原因となった。
指を切り、その後サンフランシスコ病院の救急処置室内で縫合処置を受けた、ペニシリンに対してアレルギー性の9歳の男性に、予防的「クリンダマイシン」が投与された。クリンダマイシン投与終了後3〜4週間経過して、同患者は下痢を発症した。この下痢は、痙攣、急迫、倦怠感、及び約2〜3kgの進行性の体重減少を伴った。同患者は、C.ディフィシルの伝染性株を有すると診断され、メトロニダゾールが投与された。同患者は吐気を発現し、次にバンコマイシンカプセル250mgがtdsで投与された。同患者の下痢は、メトロニダゾール、またバンコマイシンのいずれによっても非常に効果的に阻止された。投薬停止後2〜4週間内に下痢が再発し、1日当たり最大8回又は12回の下痢便を伴った。その後18ヶ月にわたり、非常に多くの下痢の再発が認められ、その都度バンコマイシンで抑えられた。バンコマイシンの用量を低減する非常に多くのプロトコールが試みられたが、同患者は継続して下痢を有した。
Claims (17)
- 腸管病原体感染症に罹患した、又はかかる感染症と一致する疾患若しくは状態を呈する動物において、かかる感染症を治療するための、又は腸管病原体感染症を発症するリスクのある動物において、かかる感染症を予防する若しくはその可能性を低減するための方法であって、(1)前記病原体を標的とする抗体又は抗体の混合物、及び(2)かかる病原体の少なくとも一部を標的としたプロバイオティクス又はプロバイオティクスの混合物を連続的に又は別々に前記動物に投与するステップを含み、抗体成分及びプロバイオティクス成分が、抗体成分が前記動物内で病原体と実質的に結合するまで、機能的に接触しない、方法。
- 腸管病原体又は前記病原体の群を標的とした抗体又は抗体の混合物、及び前記病原体又はその群の少なくとも一部を標的とするプロバイオティクス又はプロバイオティクスの混合物を含み、抗体成分がプロバイオティクス成分と機能的に接触しない組成物。
- 前記動物がヒトである、請求項1に記載の方法、又は請求項2に記載の組成物。
- 前記病原体又は病原体の群が、アエロモナス・ヒドロフィラ、セレウス菌、腸炎ビブリオ、01コレラ菌、非01コレラ菌、ビブリオ・バルニフィカス、サルモネラ・エンテリカ、腸チフス菌、パラチフス菌、サルモネラ・エンテリティデス、サルモネラ・コレラスイス、ネズミチフス菌、クロストリジウム・ディフィシレ、ボツリヌス菌、クロストリジウム・パーフリンジェンス、黄色ブドウ球菌、大腸菌、カンピロバクター・ジェジュニ、カンピロバクター・コリ、カンピロバクター・ラリ、カンピロバクター・フィタス、腸炎エルシニア、ペスト菌、仮性結核菌、プレジオモナス・シゲロイデス、リステリア菌、腸管系ウイルス、寄生虫及び真菌、管腔及び組織のマイコバクテリア、ピロリ菌、ランブル鞭毛虫、二核アメーバ、ブラストシスチス・ホミニス、並びに赤痢アメーバからなる群から選択される、請求項1に記載の方法、又は請求項2に記載の組成物。
- 腸管系ウイルスが、ロタウイルス、ノーウォーク様ウイルス、腸管アデノウイルス、コロナウイルス、及び他の非エンベロープエンテロウイルスから選択され、真菌がクリプトスポリジウム属及びサイクロスポラ属から選択され、マイコバクテリアが、マイコバクテリウム・アビウム・アビウム、ヨーネ菌、マイコバクテリウム・アビウム・シルバティカム、及びマイコバクテリウム・アビウム・コンプレックスの他の成分から選択される、請求項4に記載の方法又は組成物。
- 前記病原体又は病原体の群が、CDIと関連する病原体並びにそれらの病原体の断片、成分、及び生成物から選択される、請求項1に記載の方法、又は請求項2に記載の組成物。
- 前記抗体又は抗体の群が、ポリクロナール抗体、モノクロナール抗体、ポリクロナール抗体とモノクロナール抗体との混合物、Fab、Fab'、F(ab').sub.2、Fv、dAb、及び相補性決定領域(CDR)断片、単鎖抗体(scFv)、キメラ抗体、ヒト化抗体又はヒト抗体、二重特異性抗体、及び特異的抗原結合をもたらすのに十分な免疫グロブリンの少なくとも一部分を含有するポリペプチドから選択される、請求項1に記載の方法、又は請求項2に記載の組成物。
- 前記抗体が、毒素A、毒素B、バイナリー毒素、及び免疫化するために使用することができる上清由来の他の上清毒素、栄養型の細菌線毛、細胞外被、ピリ、芽胞、莢膜、分泌酵素、細胞膜から単離されたタンパク質及び脂質、並びに芽胞のリポ多糖画分芽胞及び芽胞画分を標的とする抗体の群から選択される、請求項7に記載の方法又は組成物。
- 分泌酵素が、コラゲナーゼ、ヒアルロニダーゼ、コアグラーゼ、及び免疫グロブリンAプロテアーゼから選択される、請求項8に記載の方法又は組成物。
- 前記抗体又は抗体の群が、ニワトリにおいて作られたIgY抗体である、請求項1に記載の方法、又は請求項2に記載の組成物。
- 前記プロバイオティクス又はプロバイオティクスの混合物が、乳酸桿菌属菌、ビフィドバクテリウム属菌、大腸菌、ユーバクテリウム属菌、サッカロミセス属菌、腸球菌属菌、バクテロイデス属菌、及び非病原性クロストリジウム属菌からなる群から選択される、請求項1に記載の方法、又は請求項2に記載の組成物。
- 非病原性クロストリジウム属が、酪酸菌及び非病原性C.ディフィシルから選択される、請求項11に記載の方法又は組成物。
- 前記プロバイオティクス又はプロバイオティクスの混合物が、in vitro又はin vivoで、前記病原体の増殖を根絶する又は抑制する能力を有する、請求項1に記載の方法、又は請求項2に記載の組成物。
- 前記感染症が、過敏性腸症候群、腹部膨満、小腸細菌の異常増殖、憩室性疾患、大腸炎、クローン病、特発性回腸炎、便秘、鼓腸、及び口臭症、運動不全状態、逆流症、偽性閉塞、腹部膨満及び旅行者下痢症、並びにパーキンソン病の便秘からなる群から選択される、請求項1に記載の方法、又は請求項2に記載の組成物。
- 過敏性腸症候群が、下痢、疼痛、便秘、これらの優位型及び混合型から選択され、憩室性疾患が憩室炎であり、大腸炎が、潰瘍性の、クローンの、リンパ性の、顕微鏡的、不定の偽膜性の、直腸炎及び感染後大腸炎から選択され、運動不全状態が胃不全麻痺である、請求項14に記載の方法又は組成物。
- 前記抗体成分及び前記プロバイオティクス成分が、別々の送達システム又は単位内に含まれる、請求項1に記載の方法、又は請求項2に記載の組成物。
- 送達システム又は単位が、カプセル、サシェ、錠剤、粒剤、丸薬、坐剤、浣腸剤の形態であり、又は経内視鏡的に、若しくは経結腸鏡的に十二指腸、回腸終末部内に、又は腸管を介して空腸内に注入可能な懸濁液の形態である、請求項16に記載の方法又は組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24527709P | 2009-09-23 | 2009-09-23 | |
US61/245,277 | 2009-09-23 | ||
PCT/IB2010/002377 WO2011036539A1 (en) | 2009-09-23 | 2010-09-22 | Therapy for enteric infections |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2013505289A true JP2013505289A (ja) | 2013-02-14 |
Family
ID=43795455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012530351A Pending JP2013505289A (ja) | 2009-09-23 | 2010-09-22 | 腸管感染症の治療法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US20120177650A1 (ja) |
EP (1) | EP2480255B1 (ja) |
JP (1) | JP2013505289A (ja) |
CN (1) | CN102711819A (ja) |
AU (3) | AU2010299552A1 (ja) |
CA (1) | CA2775050C (ja) |
ES (1) | ES2660008T3 (ja) |
PL (1) | PL2480255T3 (ja) |
WO (1) | WO2011036539A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019088230A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20220751T1 (hr) | 2010-02-01 | 2022-09-02 | Rebiotix, Inc. | Bakterioterapija clostridium difficile kolitisa |
WO2011133887A2 (en) * | 2010-04-23 | 2011-10-27 | Nutrition Physiology Company, Llc | Prevention and treatment of gastrointestinal infection in mammals |
DE102011006781A1 (de) * | 2011-04-05 | 2012-10-11 | Mat-Malta Advanced Technologies Limited | Antikörperprodukt, umfassend n spezifische Antikörper |
DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
US20120276056A1 (en) * | 2011-04-26 | 2012-11-01 | Wieslaw Janusz Bochenek | Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
UY34652A (es) * | 2012-03-02 | 2013-09-02 | Regeneron Pharma | Anticuerpos humanos frente a toxinas de clostridium difficile |
US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
CN103007046B (zh) * | 2012-12-25 | 2014-11-05 | 浙江农林大学 | 一种预防肠道疾病的灌肠液及其用途 |
AU2014212003C1 (en) | 2013-02-04 | 2020-07-16 | Seres Therapeutics, Inc. | Compositions and methods for inhibition of pathogenic bacterial growth |
EP3904502A3 (en) | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
AU2014232370B2 (en) | 2013-03-15 | 2018-11-01 | Seres Therapeutics, Inc. | Network-based microbial compositions and methods |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
CA2914636C (en) | 2013-06-05 | 2021-04-06 | Rebiotix, Inc. | Microbiota restoration therapy (mrt), compositions and methods of manufacture |
US9511099B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9694039B2 (en) | 2013-06-05 | 2017-07-04 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9511100B2 (en) | 2013-06-05 | 2016-12-06 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US9782445B2 (en) | 2013-06-05 | 2017-10-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
US10383901B2 (en) | 2013-06-05 | 2019-08-20 | Rebiotix, Inc. | Microbiota restoration therapy (MRT), compositions and methods of manufacture |
ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
RU2722482C2 (ru) | 2013-11-25 | 2020-06-01 | Серес Терапеутикс, Инк. | Синергические бактериальные композиции и способы их получения и применения |
WO2015095241A2 (en) | 2013-12-16 | 2015-06-25 | Seres Health, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
MA39710A (fr) * | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
US10513552B2 (en) * | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
US11725044B2 (en) * | 2014-10-15 | 2023-08-15 | Xenothera | Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity |
EP3065748B1 (en) | 2014-12-23 | 2017-11-22 | 4D Pharma Research Limited | A bacteroides thetaiotaomicron strain and its use in reducing inflammation |
EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
SE1550189A1 (en) * | 2015-02-19 | 2016-08-20 | Achim Biotherapeutics Ab | Therapeutic and prophylactic composition produced by microbiota |
WO2016183577A1 (en) * | 2015-05-14 | 2016-11-17 | Crestovo Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
CN104857026A (zh) * | 2015-05-18 | 2015-08-26 | 新乡医学院 | 酪酸梭菌二联活菌散对小肠结肠预防作用的研究方法 |
US10905726B2 (en) | 2015-06-09 | 2021-02-02 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
IL281424B2 (en) | 2015-06-09 | 2023-10-01 | Rebiotix Inc | Microbiota restoration treatment preparations and production methods |
US10799539B2 (en) | 2015-06-09 | 2020-10-13 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
US10828340B2 (en) | 2015-06-09 | 2020-11-10 | Rebiotix, Inc. | Microbiota restoration therapy (MRT) compositions and methods of manufacture |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EA038405B1 (ru) | 2015-06-15 | 2021-08-24 | 4Д Фарма Рисёрч Лимитед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ШТАММЫ БАКТЕРИИ Bifidobacterium breve, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПАТОЛОГИЧЕСКОГО СОСТОЯНИЯ, ОПОСРЕДОВАННОГО IL-17 ИЛИ Th17 |
AU2016278067B2 (en) | 2015-06-15 | 2022-09-22 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
SI3307288T1 (sl) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Spojine, ki vsebujejo bakterijske seve |
CN104961826B (zh) * | 2015-07-14 | 2017-12-05 | 大连理工大学 | 一种金黄色葡萄球菌特异性鸡卵黄免疫球蛋白可变区单链抗体及用途 |
EP3341000A4 (en) * | 2015-08-24 | 2019-02-20 | Nubyiota LLC | SYSTEMS AND METHODS FOR THE TREATMENT OF DYSBIOSIS USING BACTERIAL POPULATIONS DERIVED FROM FECES |
MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
WO2017143386A1 (en) * | 2016-02-25 | 2017-08-31 | Borody Thomas J | Compositions and methods of treatment of chronic infectious diseases |
SI3313423T1 (sl) | 2016-03-04 | 2019-07-31 | 4D Pharma Plc | Sestavki, ki vsebujejo bakterijske seve Blautia za zdravljenje visceralne preobčutljivosti |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
EP3630136B1 (en) | 2017-05-22 | 2021-04-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
WO2018229188A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
IL292373A (en) | 2017-06-14 | 2022-06-01 | 4D Pharma Res Ltd | Preparations containing bacterial strains of the Megasphere genus and their use |
KR20200040277A (ko) | 2017-08-14 | 2020-04-17 | 세레스 테라퓨틱스, 인코포레이티드 | 담즙정체성 질환 치료를 위한 조성물 및 방법 |
CN108220200B (zh) * | 2018-02-08 | 2020-06-23 | 中国人民解放军军事科学院军事医学研究院 | 用于治疗结肠炎症的微厌氧细菌及其应用 |
US10973918B2 (en) * | 2018-10-03 | 2021-04-13 | Anubis Bio Corporation | Composition and methods for treating acute diarrhea and enteric infections in animals |
US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
CN111345473A (zh) * | 2020-03-13 | 2020-06-30 | 珠海华敏医药科技有限公司 | 一种含卵黄抗体IgY的益生菌组合物及应用制剂 |
TW202146036A (zh) * | 2020-04-28 | 2021-12-16 | 香港中文大學 | 針對covid-19的微生物的治療和診斷用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020577A1 (en) * | 1995-12-06 | 1997-06-12 | Pharma Pacific Pty. Ltd. | Improved therapeutic formulation and method |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994021284A1 (en) * | 1993-03-15 | 1994-09-29 | Pharma Pacific Pty. Ltd. | Therapeutic formulation and method |
EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | MULTI-CHAMBER HARD CAPSULES WITH CONTROLLED DELIVERY CHARACTERISTICS |
KR100387245B1 (ko) * | 1997-10-17 | 2003-08-19 | 일양약품주식회사 | 유산균의안정화를위한미세장용성코팅과립 |
CZ287989B6 (cs) * | 1998-03-20 | 2001-03-14 | Medipharm Cz, S. R. O. | Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat |
WO2000024266A2 (en) * | 1998-10-26 | 2000-05-04 | Galagen, Inc. | Soy and immunoglobulin compositions |
KR100324441B1 (ko) * | 1999-02-08 | 2002-02-27 | 이은선 | 위염, 위궤양, 십이지장궤양 예방을 위한 식품 |
US20030185856A1 (en) * | 2001-01-05 | 2003-10-02 | Nam-Hyung Lee | Method for the production of the egg containing anti-pathogenic bacteria specific antbodies(igy) and the yogurt and ice cream containing the igy |
US20050266069A1 (en) * | 2002-09-06 | 2005-12-01 | Simmons Donald L | Stable probiotic microsphere compositions and their methods of preparation |
WO2005005481A2 (en) * | 2003-07-10 | 2005-01-20 | Avitek Pharma Inc. | Combination therapy for gastroenteric diseases caused by microorganisms |
US7611712B2 (en) * | 2003-10-23 | 2009-11-03 | Nelson M. Karp | Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide |
WO2009092810A2 (en) * | 2008-01-24 | 2009-07-30 | Bacterfield Oü | Single pharmaceutical composition containing antibiotics and probiotics |
-
2010
- 2010-09-22 AU AU2010299552A patent/AU2010299552A1/en not_active Abandoned
- 2010-09-22 ES ES10818479.7T patent/ES2660008T3/es active Active
- 2010-09-22 EP EP10818479.7A patent/EP2480255B1/en not_active Not-in-force
- 2010-09-22 WO PCT/IB2010/002377 patent/WO2011036539A1/en active Application Filing
- 2010-09-22 US US13/497,118 patent/US20120177650A1/en not_active Abandoned
- 2010-09-22 JP JP2012530351A patent/JP2013505289A/ja active Pending
- 2010-09-22 CN CN2010800427469A patent/CN102711819A/zh active Pending
- 2010-09-22 CA CA2775050A patent/CA2775050C/en not_active Expired - Fee Related
- 2010-09-22 PL PL10818479T patent/PL2480255T3/pl unknown
-
2016
- 2016-09-23 AU AU2016231612A patent/AU2016231612A1/en not_active Abandoned
-
2017
- 2017-11-30 US US15/828,260 patent/US20180155410A1/en not_active Abandoned
-
2018
- 2018-11-02 AU AU2018256633A patent/AU2018256633A1/en not_active Abandoned
- 2018-12-27 US US16/233,419 patent/US20190276518A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020577A1 (en) * | 1995-12-06 | 1997-06-12 | Pharma Pacific Pty. Ltd. | Improved therapeutic formulation and method |
Non-Patent Citations (1)
Title |
---|
JPN6014038566; Fulton, RM: Poultry Science Vol.81, No.1, 2002, pp.34-40 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019088230A1 (ja) * | 2017-11-02 | 2019-05-09 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
JPWO2019088230A1 (ja) * | 2017-11-02 | 2020-11-26 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
JP7075671B2 (ja) | 2017-11-02 | 2022-05-26 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
JP7329279B2 (ja) | 2017-11-02 | 2023-08-18 | オーストリッチファーマ株式会社 | 細菌感染症用ダチョウ抗体 |
Also Published As
Publication number | Publication date |
---|---|
CA2775050C (en) | 2020-07-14 |
US20180155410A1 (en) | 2018-06-07 |
CA2775050A1 (en) | 2011-03-31 |
AU2010299552A1 (en) | 2012-04-05 |
US20190276518A1 (en) | 2019-09-12 |
US20120177650A1 (en) | 2012-07-12 |
EP2480255A1 (en) | 2012-08-01 |
AU2016231612A1 (en) | 2016-10-20 |
EP2480255A4 (en) | 2013-03-20 |
ES2660008T3 (es) | 2018-03-20 |
PL2480255T3 (pl) | 2018-07-31 |
CN102711819A (zh) | 2012-10-03 |
EP2480255B1 (en) | 2017-11-22 |
WO2011036539A1 (en) | 2011-03-31 |
AU2018256633A1 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2775050C (en) | Therapy for enteric infections | |
Warny et al. | Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine | |
JP6121907B2 (ja) | 広域の、非定型の、または混合の臨床応用における治療のための組成物および方法 | |
JP2018535254A (ja) | 便微生物叢関連療法のための組成物及び方法 | |
JP2023010890A (ja) | 潰瘍性大腸炎を治療するための方法 | |
US20220047646A1 (en) | Compositions for management of disorders of the gastrointestinal tract | |
KR20220049524A (ko) | 위장관 장애의 치료를 위한 방법 및 제품 | |
US11213549B2 (en) | Compositions and method for treating primary sclerosing cholangitis and related disorders | |
US20070280949A1 (en) | Combination Therapy for Gastroenteric Diseases Caused by Microorganisms | |
US20180092949A1 (en) | Prevention or treatment of an infection by bacteroides thetaiotaomicron | |
Isfahani et al. | The effect of capsulated and noncapsulated egg-yolk–specific antibody to reduce colonization in the intestine of Salmonella enterica ssp. enterica serovar Infantis–challenged broiler chickens | |
EP2957570A1 (en) | Polyclonal antibodies against clostridium difficile and uses thereof | |
US20200164000A1 (en) | Compositions and methods for treating disorders related to a gut dysbiosis | |
US20180099011A1 (en) | Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders | |
Macbeth et al. | A dysbiotic gut microbiome suppresses antibody mediated-protection against Vibrio cholerae | |
JP7329279B2 (ja) | 細菌感染症用ダチョウ抗体 | |
Villa et al. | Fecal Matter Implantation as a Way to Fight Diarrhea-Causing Microorganisms | |
Gherlan | Current and future approaches in Clostridioides Difficile management. | |
Chen et al. | Saccharomyces spp. | |
WO2021142358A1 (en) | Compositions and methods for treating hepatic encephalopathy (he) | |
WO2021142353A1 (en) | Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140916 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150316 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150824 |